Federal Trade Commission accuses three drug middlemen of inflating insulin prices
In a lawsuit, the FTC accused Optum Rx, Caremark and Express Scripts of creating "a broken rebate system that inflated insulin drug prices, boosting PBM (prescription drug benefit managers) profits at the expense of vulnerable patients.
A Federal Trade Commission (FTC) report found that social and video streaming services pose serious privacy risks, especially ...
CNBC on MSN6d
In federal trial, Michael Kors says it's harder to sell handbags in TikTok and Taylor Swift eraFashion designer Michael Kors testified Monday about competition in the handbag industry. The Federal Trade Commission ...
The federal government is suing some pharmacy benefit managers over a system of drug rebates that regulators say has made the ...
Cigna Group’s Express Scripts sued the US Federal Trade Commission over a recent report that the company said demonizes ...
Last month, the Federal Trade Commission (FTC) and U.S. Department of Justice (DOJ) jointly hosted a public meeting of the interagency “Strike ...
California courts were home to the most federal trade secrets litigation over the past three years, according to a report ...
Three companies that process about 80% of prescriptions in the United States — Caremark, Express Scripts and OptumRx — have ...
The investigation also highlights the companies' failure to adequately protect users, particularly children and teenagers.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback